CTAS vs TECH · P/E 51, rev $10.34B vs P/E 65, rev $1.22B
Cintas Corporation (CTAS) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the CTAS and TECH stock pages for the full models.
Not investment advice.